Developer docs
API playgroundTry for free, no card

Search company profiles

Hoba Therapeutics

Full company profile

uuid0002k8u

Namestring
Hoba Therapeutics
Legal namestring
Hoba Therapeutics ApS
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
therapeutic protein development, neuropathic pain treatment, biopharmaceutical drug discovery, sensorineural hearing loss therapy, preclinical biotech research
Industry3 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
NAICS code1 code
  • Scientific Research and Development Services5417
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development & Licensing
TypeLicensing Royalties
Description

Pre-revenue biotech company. Revenue expected to come from licensing deals, co-development partnerships, and eventual product commercialization upon regulatory approval. The company is developing two therapeutic protein candidates (HB-086 for neuropathic pain, HB-097 for hearing loss) through preclinical and clinical development stages.

hobatherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hoba Therapeutics develops proprietary therapeutic protein drug candidates based on the endogenous human neurotrophic factors meteorin and cometin. Its lead candidate HB-086 (recombinant human meteorin) is in late preclinical development for chronic neuropathic pain, with target indications including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. The second candidate HB-097 (recombinant human cometin) is in preclinical development for sensorineural hearing loss, with ototoxic hearing loss as the target indication.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Sustained analgesic effect lasting up to 3 weeks in preclinical studies
+2 more records
Product overview1 text field

Hoba Therapeutics is an early-stage Danish biotech developing two novel biopharmaceutical drugs based on proprietary neurotrophic factors (meteorin and cometin). The core portfolio consists of HB-086, a recombinant human meteorin for chronic neuropathic pain conditions (CIPN, trigeminal neuralgia), and HB-097, a recombinant human cometin for sensorineural hearing loss. Both are therapeutic proteins and the only members of a recently discovered family of neurotrophic factors with unique actions on sensory nerve cells and surrounding support cells.

Product and service2 records
1HB-086 (Meteorin)
CategoryTherapeutic protein — chronic neuropathic pain
Description

HB-086 is a recombinant human meteorin therapeutic protein in late preclinical development for chronic neuropathic pain. It is a non-opioid treatment targeting the peripheral nervous system, intended to reverse neuropathic pain and address the underlying cause of disease rather than masking symptoms. Target indications include Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. Preclinical data show robust, long-lasting analgesic effect up to three weeks.

2HB-097 (Cometin)
CategoryTherapeutic protein — sensorineural hearing loss
Description

HB-097 is a recombinant human cometin therapeutic protein in preclinical development for sensorineural hearing loss. Preclinical data show both preventive effects (by protecting nerve cells) and regenerative effects (by reversing already induced damage). Target indication is ototoxic hearing loss, with potential also for age-related and noise-induced hearing loss.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Part of consortium receiving DKK 18.4M funding. Multidisciplinary team led by Professor M. Hirano studying neuropathic pain caused by chemotherapy, including basic researchers, clinical neurologists and oncologists.

2University of Copenhagen (NNCPR)
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Part of consortium. Novo Nordisk Fund's Center for Protein Research, led by Prof. Jesper V. Olsen, provides proteomics expertise for dynamic protein-protein interactions and protein expression profiling.

hobatherapeutics.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Part of consortium. Christian B. Vægter's group internationally recognized for research of peripheral neuropathies and role of glial cells in nervous system.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2020-01-01
Description

Global leader in cell line development providing best-in-class modular technology and specialized solutions enabling rapid discovery, development and commercialization of innovative medicines and vaccines.

Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2020-01-01
Description

Innovative Partner Research Organization (iPRO) providing science-driven discovery services to life sciences companies in pharma, biotech, animal health, agrochemical and nutrition sectors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing regenerative small molecules and biologics for hearing loss and neurotology; directly comparable to Hoba's HB-097 in regenerative approach to sensorineural hearing loss.

TypeEmerging player
Description

Preclinical/early-clinical biotech developing gene therapy-based approaches to chronic neuropathic pain; an emerging player using a different modality but addressing the same unmet need as HB-086.

3Eliem Therapeutics
TypeDirect peer
Description

Clinical-stage biotech focused on CNS indications including neuropathic pain and epilepsy; comparable in therapeutic-area focus, development stage and small-cap biotech profile to Hoba.

TypeDirect peer
Description

Clinical-stage biotech developing NMDA-receptor modulators (e.g., NYX-2925) for chronic neuropathic pain; directly comparable in indication and development-stage biotech profile to Hoba's HB-086 program.

TypeDirect peer
Description

Clinical-stage biotech developing enginerin (a neurotrophic factor biologic) for diabetic peripheral neuropathy and other neuropathic conditions; the closest mechanistic analogue to Hoba's HB-086 meteorin program.

TypeDirect peer
Description

Clinical-stage biotech developing regenerative therapeutics for sensorineural hearing loss; directly comparable to Hoba's HB-097 program in modality (regenerative biologic) and indication.

TypeBroad incumbent
Description

Large commercial-stage biopharma developing non-opioid pain therapies (e.g., VX-548/Journavx for acute pain and follow-on NaV1.8 programs); serves as the broad incumbent setting the competitive bar in non-opioid pain where Hoba's HB-086 also competes.

TypeEmerging player
Description

Biotech developing non-opioid Nav1.7-targeted therapeutics for pain; overlaps with Hoba's mission of replacing opioids in chronic pain and represents an emerging competitive modality in the same indication.

9Otonomy
TypeDirect peer
Description

Clinical-stage biotech developing therapeutics for ear disorders including sensorineural hearing loss; comparable to HB-097 in indication and small-cap biotech profile.

TypeEmerging player
Description

European biotech developing small-molecule therapeutics for sensorineural hearing loss; an emerging regional peer with overlapping indication to HB-097.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hoba Therapeutics

Biopharmaceutical Therapeuticshobatherapeutics.com

Hoba Therapeutics firmographics

Firmographics
Name
Hoba Therapeutics
Legal name
Hoba Therapeutics ApS
Website
https://hobatherapeutics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Hoba Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)

Keywords

  • Therapeutic protein development
  • Neuropathic pain treatment
  • Biopharmaceutical drug discovery
  • Sensorineural hearing loss therapy
  • Preclinical biotech research

Where Hoba Therapeutics is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Hoba Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development & Licensing: Pre-revenue biotech company. Revenue expected to come from licensing deals, co-development partnerships, and eventual product commercialization upon regulatory approval. The company is developing two therapeutic protein candidates (HB-086 for neuropathic pain, HB-097 for hearing loss) through preclinical and clinical development stages.

Go-to-market motion1 record

Marketing channels4 records

Hoba Therapeutics product offering

Product offering

Core offering

Hoba Therapeutics develops proprietary therapeutic protein drug candidates based on the endogenous human neurotrophic factors meteorin and cometin. Its lead candidate HB-086 (recombinant human meteorin) is in late preclinical development for chronic neuropathic pain, with target indications including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. The second candidate HB-097 (recombinant human cometin) is in preclinical development for sensorineural hearing loss, with ototoxic hearing loss as the target indication.

Product overview

Hoba Therapeutics is an early-stage Danish biotech developing two novel biopharmaceutical drugs based on proprietary neurotrophic factors (meteorin and cometin). The core portfolio consists of HB-086, a recombinant human meteorin for chronic neuropathic pain conditions (CIPN, trigeminal neuralgia), and HB-097, a recombinant human cometin for sensorineural hearing loss. Both are therapeutic proteins and the only members of a recently discovered family of neurotrophic factors with unique actions on sensory nerve cells and surrounding support cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • HB-086 (Meteorin) HB-086 is a recombinant human meteorin therapeutic protein in late preclinical development for chronic neuropathic pain. It is a non-opioid treatment targeting the peripheral nervous system, intended to reverse neuropathic pain and address the underlying cause of disease rather than masking symptoms. Target indications include Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. Preclinical data show robust, long-lasting analgesic effect up to three weeks.
  • HB-097 (Cometin) HB-097 is a recombinant human cometin therapeutic protein in preclinical development for sensorineural hearing loss. Preclinical data show both preventive effects (by protecting nerve cells) and regenerative effects (by reversing already induced damage). Target indication is ototoxic hearing loss, with potential also for age-related and noise-induced hearing loss.

Quantifiable outcome

  • Sustained analgesic effect lasting up to 3 weeks in preclinical studies
  • +2 more outcomes

Companies that use Hoba Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Hoba Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Hoba Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered supporting.

  • Columbia University (Dept. Neurology)supportingStrategic or Co-development Partner · 1 January 2020Part of consortium receiving DKK 18.4M funding. Multidisciplinary team led by Professor M. Hirano studying neuropathic pain caused by chemotherapy, including basic researchers, clinical neurologists and oncologists.
  • University of Copenhagen (NNCPR)supportingStrategic or Co-development Partner · 1 January 2020Part of consortium. Novo Nordisk Fund's Center for Protein Research, led by Prof. Jesper V. Olsen, provides proteomics expertise for dynamic protein-protein interactions and protein expression profiling.
  • Aarhus University (Department of Biomedicine)supportingStrategic or Co-development Partner · 1 January 2020Part of consortium. Christian B. Vægter's group internationally recognized for research of peripheral neuropathies and role of glial cells in nervous system.
  • Selexis SAsupportingTechnology or Integration · 1 January 2020Global leader in cell line development providing best-in-class modular technology and specialized solutions enabling rapid discovery, development and commercialization of innovative medicines and vaccines.
  • AxxamsupportingTechnology or Integration · 1 January 2020Innovative Partner Research Organization (iPRO) providing science-driven discovery services to life sciences companies in pharma, biotech, animal health, agrochemical and nutrition sectors.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Hoba Therapeutics competitors and assessment

Company assessment

Direct peers

  • Pipeline Therapeutics: Clinical-stage biotech developing regenerative small molecules and biologics for hearing loss and neurotology; directly comparable to Hoba's HB-097 in regenerative approach to sensorineural hearing loss.
  • Eliem Therapeutics: Clinical-stage biotech focused on CNS indications including neuropathic pain and epilepsy; comparable in therapeutic-area focus, development stage and small-cap biotech profile to Hoba.
  • Aptinyx: Clinical-stage biotech developing NMDA-receptor modulators (e.g., NYX-2925) for chronic neuropathic pain; directly comparable in indication and development-stage biotech profile to Hoba's HB-086 program.
  • Helixmith: Clinical-stage biotech developing enginerin (a neurotrophic factor biologic) for diabetic peripheral neuropathy and other neuropathic conditions; the closest mechanistic analogue to Hoba's HB-086 meteorin program.
  • Frequency Therapeutics: Clinical-stage biotech developing regenerative therapeutics for sensorineural hearing loss; directly comparable to Hoba's HB-097 program in modality (regenerative biologic) and indication.
  • Otonomy: Clinical-stage biotech developing therapeutics for ear disorders including sensorineural hearing loss; comparable to HB-097 in indication and small-cap biotech profile.

Emerging players

  • Navega Therapeutics: Preclinical/early-clinical biotech developing gene therapy-based approaches to chronic neuropathic pain; an emerging player using a different modality but addressing the same unmet need as HB-086.
  • Latigo Biotherapeutics: Biotech developing non-opioid Nav1.7-targeted therapeutics for pain; overlaps with Hoba's mission of replacing opioids in chronic pain and represents an emerging competitive modality in the same indication.
  • Acousia Therapeutics: European biotech developing small-molecule therapeutics for sensorineural hearing loss; an emerging regional peer with overlapping indication to HB-097.

Broad incumbents

  • Vertex Pharmaceuticals: Large commercial-stage biopharma developing non-opioid pain therapies (e.g., VX-548/Journavx for acute pain and follow-on NaV1.8 programs); serves as the broad incumbent setting the competitive bar in non-opioid pain where Hoba's HB-086 also competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Hoba Therapeutics social profiles

Digital presence

Hoba Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hoba Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Hoba Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hoba Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hoba Therapeutics

What does Hoba Therapeutics do?

Hoba Therapeutics develops proprietary therapeutic protein drug candidates based on the endogenous human neurotrophic factors meteorin and cometin. Its lead candidate HB-086 (recombinant human meteorin) is in late preclinical development for chronic neuropathic pain, with target indications including Chemotherapy-Induced Peripheral Neuropathy (CIPN) and trigeminal neuralgia. The second candidate HB-097 (recombinant human cometin) is in preclinical development for sensorineural hearing loss, with ototoxic hearing loss as the target indication.

Is Hoba Therapeutics a public or private company?

Hoba Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hoba Therapeutics founded?

Hoba Therapeutics was founded in 2016. It employs 1 to 10 people.

Where is Hoba Therapeutics based?

Hoba Therapeutics is headquartered in Copenhagen, Denmark, in the Europe region.

How does Hoba Therapeutics make money?

One revenue line is on record: drug Development & Licensing.

Who are Hoba Therapeutics's main competitors?

Direct peers on record are Pipeline Therapeutics, Eliem Therapeutics, Aptinyx, Helixmith, Frequency Therapeutics and Otonomy. Emerging players are Navega Therapeutics, Latigo Biotherapeutics and Acousia Therapeutics. Vertex Pharmaceuticals is listed as a broad incumbent.

Does Hoba Therapeutics have an API?

No public API is recorded for Hoba Therapeutics.

What industry is Hoba Therapeutics in?

Hoba Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 5417.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsHoba Therapeutics Raises EUR 23M in Series A FundingHoba Therapeutics raised EUR 23M in Series A funding led by Indaco Venture Partners and Medical Incubator Japan, with participation from Novo Holdings, Eir Ventures, and EIFO. The company will use the funds to advance HB-086 through late pre-clinical development to Phase 1 clinical studies for chemotherapy-induced peripheral neuropathy.IndacosgrINDACO VENTURE PARTNERS – HOBA THERAPEUTICS RAISES EUR 23 MILLION IN A SERIES A TO ADVANCE NEW DRUG CANDIDATE AGAINST CHORNIC NEUROPATHIC PAINHoba Therapeutics has raised EUR 23 million in the first close of its Series A financing to advance its drug candidate HB-086 for chronic neuropathic pain. The round was co-led by Indaco Venture Partners and Medical Incubator Japan, with participation from Novo Holdings, Eir Ventures, and other investors. These funds will support the transition of HB-086 into Phase 1 clinical studies for chemotherapy-induced peripheral neuropathy.PR NewswireHoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic painHoba Therapeutics, a Danish biotech company, has successfully raised EUR 23 million in a Series A financing round, which will aid in the development of its drug candidate HB-086 for chronic neuropathic pain. The financing, co-led by Indaco Venture Partners and Medical Incubator Japan, includes contributions from several existing investors, including Novo Holdings and the Export and Investment Fund of Denmark. This funding aims to advance HB-086 through late pre-clinical development and into Phase 1 clinical studies for treating Chemotherapy-Induced Peripheral Neuropathy.ArcticstartupDenmark’s Hoba Therapeutics raises €23M Series A to progress novel drug for chronic neuropathic pain treatmentDenmark-based Hoba Therapeutics secured €23 million in Series A funding led by Indaco Venture Partners and Medical Incubator Japan to advance its novel non-opioid drug, HB-086. The capital will be used to progress the compound through late pre-clinical development and Phase 1 clinical studies targeting Chemotherapy-Induced Peripheral Neuropathy (CIPN).